Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-07-08
2004-03-02
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700, C514S800000, C530S313000, C530S326000, C530S327000, C530S328000, C530S329000, C424S468000, C424S488000, C424S489000, C424S499000
Reexamination Certificate
active
06699833
ABSTRACT:
BACKGROUND OF THE INVENTION
A variety of diseases and clinical disorders are treated by the administration of a pharmaceutically active peptide. One such example is prostate cancer, which is a sex hormone dependent cancer and which can be treated by administration of a luteinizing hormone releasing hormone (LHRH) analogue that disturbs the production of luteinizing hormone (LH), which regulates the synthesis of male hormones. In particular, to decrease LH production, peptidic analogues of LHRH that act as superagonists of the luteinizing hormone releasing hormone receptor, such as leuprolide and goserelin, have been used.
In many instances, the therapeutic effectiveness of a pharmaceutically active peptide depends upon its continued presence in vivo over prolonged time periods. To achieve continuous delivery of the peptide in vivo, a sustained release or sustained delivery formulation is desirable, to avoid the need for repeated administrations. One approach for sustained drug delivery is by microencapsulation, in which the active ingredient is enclosed within a polymeric membrane to produce microparticles. For example, LHRH superagonists, such as leuprolide and goserelin, typically are encapsulated within a microparticle comprising a poly-lactide/poly-glycolide copolymer to prepare formulations suitable for depot injection that provide sustained delivery of the superagonist over several weeks to months (see e.g., U.S. Pat. Nos. 4,675,189; 4,677,191; 5,480,656 and 4,728,721).
Additional sustained delivery formulations for administering pharmaceutically active peptides in vivo continuously for prolonged time periods are needed.
SUMMARY OF THE INVENTION
The present invention provides pharmaceutical compositions comprising a stable water-insoluble complex composed of a peptide, preferably a pharmaceutically active peptide, and a carrier macromolecule that allow for sustained delivery of the peptide in vivo upon administration of the complex. Accordingly, the complex of the invention can permit continuous delivery of a pharmaceutically active peptide to a subject for prolonged periods of time, e.g., one month. Moreover, the association of the peptide and the carrier macromolecule in a tight, stable complex allows for loading of high concentrations of the peptide into the formulation.
The complex of the invention is formed by combining the peptide and the carrier macromolecule under conditions such that a water-insoluble complex is formed, e.g., aqueous solutions of the peptide and carrier macromolecule are mixed until the complex precipitates. The complex may be in the form of a solid (e.g., a paste, granules, a powder or a lyophilizate) or the powdered form of the complex can be pulverized finely enough to form stable liquid suspensions or semi-solid dispersions. The complex of the invention is suitable for sterilization, such as by gamma irradiation or electron beam irradiation, prior to administration in vivo.
In a preferred embodiment, the peptide of the water-insoluble complex is an LHRH analogue, more preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose.
Method for treating a subject for a condition treatable with an LHRH analogue by administering to the subject an LHRH-analogue-containing composition of the invention are also provided. In a preferred embodiment, the treatment methods of the invention are used in the treatment of prostate cancer.
REFERENCES:
patent: 4016100 (1977-04-01), Suzuki et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4639370 (1987-01-01), Carli
patent: 4675189 (1987-06-01), Kent et al.
patent: 4677191 (1987-06-01), Tanaka et al.
patent: 4728721 (1988-03-01), Yamamoto et al.
patent: 4775535 (1988-10-01), Lowey
patent: 4789547 (1988-12-01), Song et al.
patent: 4913906 (1990-04-01), Friedman et al.
patent: 4980150 (1990-12-01), Keith
patent: 5015479 (1991-05-01), Mulligan et al.
patent: 5028430 (1991-07-01), Sanders et al.
patent: 5049395 (1991-09-01), Chang
patent: 5128142 (1992-07-01), Mulligan et al.
patent: 5180522 (1993-01-01), Kawashima et al.
patent: 5192741 (1993-03-01), Orsolini et al.
patent: 5314915 (1994-05-01), Rencher
patent: 5326571 (1994-07-01), Wright et al.
patent: 5366734 (1994-11-01), Hutchinson
patent: 5439688 (1995-08-01), Orsolini et al.
patent: 5462749 (1995-10-01), Rencher
patent: 5480656 (1996-01-01), Okada et al.
patent: 5487898 (1996-01-01), Lu et al.
patent: 5520927 (1996-05-01), Kim et al.
patent: 5540937 (1996-07-01), Billot et al.
patent: 5545409 (1996-08-01), Laurencin et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5629009 (1997-05-01), Laurencin et al.
patent: 5656297 (1997-08-01), Bernstein et al.
patent: 5688530 (1997-11-01), Bodmer et al.
patent: 5700486 (1997-12-01), Canal et al.
patent: 5711968 (1998-01-01), Tracy et al.
patent: 5968895 (1999-10-01), Gefter et al.
patent: 6180608 (2001-01-01), Gefter et al.
patent: 19712718 (1999-10-01), None
patent: 0 328 090 (1989-08-01), None
patent: 0 467 389 (1992-01-01), None
patent: 0 601 799 (1994-06-01), None
patent: 645136 (1995-03-01), None
patent: 2455459 (1981-01-01), None
patent: 63310827 (1988-12-01), None
patent: WO 88/05661 (1988-08-01), None
patent: WO 92/11844 (1992-07-01), None
patent: WO 92/20349 (1992-11-01), None
patent: WO 94/08566 (1994-04-01), None
patent: WO 94/15587 (1994-07-01), None
patent: WO 96/40757 (1996-12-01), None
patent: WO 97/22357 (1997-06-01), None
Hussain, M.A. et al., “Injectable Suspensions for Prolonged Release Nalbuphine,”Drug Devel. and Industrial Pharmacy17(1):67-76 (1991).
Langer, R. (1982), “Controlled Release of Macromolecules,”Chemtech 12(2):98-105.
Paavola, A. et al., “Controlled Release of Lidocaine from Injectable Gels and Efficacy in Rat Sciatic Nerve Block,”Pharm. Res.12(12):1997-2002 (1995).
Palyi, I. et al. (1996), “Effect of Gonadotropin-Releasing Hormone Analogs and Their Conjugates on Gonadotropin-Releasing Hormone Receptor-Positive Human Cancer Cell Lines”Cancer Detection and Prevention 20(2):1462-52.
Vincze, B. et al. (1994) “Antitumour Effect of a Gonadotropin-releasing-hormone Antagonist (MI-1544) and its Conjugate on Human Breast Cancer Cells and their Xenografts,”J Cancer Res Clin Oncol. 120(10):578-84.
Barker Nicholas
Gefter Malcolm L.
Molineaux Christopher J.
Musso Gary
DeConti, Jr. Esq. Guilio A.
Kam Chih-Min
Lahive & Cockfield LLP
Low Christopher S. F.
Praecis Pharmaceuticals Inc.
LandOfFree
Pharmaceutical formulations for sustained drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations for sustained drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations for sustained drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3211285